Compare XPOF & IKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | XPOF | IKT |
|---|---|---|
| Founded | 2017 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Services-Misc. Amusement & Recreation | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 273.4M | 220.5M |
| IPO Year | 2021 | 2020 |
| Metric | XPOF | IKT |
|---|---|---|
| Price | $6.79 | $1.82 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 6 | 5 |
| Target Price | ★ $8.13 | $5.00 |
| AVG Volume (30 Days) | 548.2K | ★ 583.1K |
| Earning Date | 05-07-2026 | 03-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 35.24 | ★ 57.76 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $11,092,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $6.63 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $3.83 | $1.33 |
| 52 Week High | $11.14 | $2.26 |
| Indicator | XPOF | IKT |
|---|---|---|
| Relative Strength Index (RSI) | 65.44 | 61.33 |
| Support Level | $6.64 | $1.63 |
| Resistance Level | $7.08 | $1.91 |
| Average True Range (ATR) | 0.34 | 0.08 |
| MACD | 0.16 | 0.02 |
| Stochastic Oscillator | 88.33 | 100.00 |
Xponential Fitness Inc is a franchisor of boutique health and wellness brands. It operates a diversified platform of five brands spanning across verticals, including Pilates, barre, stretching, functional training, and yoga. Through its subsidiary, it offers an energetic, accessible, and personalized workout experience led by qualified instructors in studio locations throughout North America and internationally. The company's portfolio of brands includes Club Pilates; StretchLab; YogaSix; Pure Barre; and BFT. It operates in a single segment of the franchise business of its health and wellness brands.
Inhibikase Therapeutics Inc a clinical-stage pharmaceutical company developing therapeutics to modify the course of cardiopulmonary diseases, namely, Pulmonary Arterial Hypertension (PAH), in which aberrant signaling through type III receptor tyrosine kinases, including platelet derived growth factor receptors and a stem cell factor receptor, known as c-Kit, has been implicated. Its product candidate is IKT-001, a prodrug of imatinib mesylate (imatinib), for PAH which is an orphan indication. The company has developed its own portfolio of protein kinase inhibitors to treat bacterial and viral infections, including viral infections in the brain. It has one reporting segment, which is the business of developing protein kinase inhibitor therapeutics.